Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])

American Journal of Cardiology

Volumn 104, Issue 11, 2009, Pages 1484-1489

  Cowan, Brett R ^a   Young, Alistair A ^a   Anderson, Craig ^a,b   Doughty, Robert N ^a   Krittayaphong, Rungroj ^g   Lonn, Eva ^h   Marwick, Thomas H ^c   Reid, Chris M ^d,e   Sanderson, John E ^j,k   Schmieder, Roland E ⁱ   Teo, Koon ^h   Wadham, Angela K ^a   Worthley, Stephen G ^f   Yu, Cheuk Man ^k   Yusuf, Salim ^h   Jennings, Garry L ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g MAHIDOL UNIVERSITY   (Thailand)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAMIPRIL; TELMISARTAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATHEROSCLEROSIS; BENZIMIDAZOLES; BENZOATES; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; RAMIPRIL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 71749085323     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.07.018     Document Type: Article

References (28)

1. Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F., Ramos B., Hilbrich L., Pogue J., Schumacher H., and ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
2. Sleight P. The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol 42 (2005) S50-S56
3. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on CV events in high-risk patients. N Engl J Med 342 (2000) 145-153
4. Lonn E., Shaikholeslami R., Yi Q., Bosch J., Sullivan B., Tanser P., Magi A., and Yusuf S. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. A substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 43 (2004) 2200-2206
5. The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
6. Pattynama P., De Roos A., Van der Wall E., and Van Voorthuisen A. Evaluation of cardiac function with magnetic resonance imaging. Am Heart J 128 (1994) 595-607
7. Myerson S.G., Bellenger N.G., and Pennell D.J. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 39 (2002) 750-755
8. Bottini P., Carr A., Prisant L., Flickinger F., Allison J., and Gottdiener J. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 8 (1995) 221-228
9. Pattynama P.M.T., Lamb H.J., van der Velde E.A., van der Wall E.E., and de Roos A. Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Radiology 187 (1993) 261-268
10. Reichek N. Magnetic resonance imaging for assessment of myocardial function. Magn Reson Q 7 (1991) 255-274
11. Fieno D., Jaffe W., Simonetti O., Judd R., and Finn J. TrueFISP. Assessment of accuracy for measurement of left ventricular mass in an animal model. J Magn Reson Imaging 15 (2002) 526-531
12. Lorenz C., Walker E., Morgan V., Klein S., and Graham T. Normal human right and left ventricular mass, systolic function and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1 (1999) 7-21
13. Tseng W., Liao T., and Wang J. Normal systolic and diastolic functions of the left ventricle and left atrium by cine magnetic resonance imaging. J Cardiovasc Magn Reson 4 (2002) 443-457
14. Cowan B.R., Young A.A., Anderson C., Doughty R.N., Krittayaphong R., Lonn E., Marwick T.H., Reid C.M., Sanderson J.E., Schmieder R.E., Teo K., Wadham A.K., Worthley S.G., Yo C.-M., Yusuf S., and Jennings G.L. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clin Res Cardiol 98 (2009) 421-433
15. Young A., Cowan B., Thrupp S., Hedley W., and Dell'Italia L. Left ventricular mass and volume: fast calculation with guide-point modeling on MR images. Radiology 216 (2000) 597-602
16. White H., Norris R., Brown M., Brandt P., Whitlock R., and Wild C. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 (1987) 44-51
17. Klingbeil A.U., Schneider M.P., Martus P., Messereli F.H., and Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
18. Schmieder R.E., Schlaich M.P., Klingbeil A.U., and Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 13 (1998) 564-569
19. Matchar D.B., McCrory D.C., Orlando L.A., Patel M.R., Patel U.D., Patwardhan M.B., Powers B., Samsa G.P., and Gray R.N. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148 (2008) 16-29
20. Galzerano D., Tammaro P., Cerciello A., Breglio R., Mallardo M., Lama D., Tuccillo B., and Capogrosso P. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens 18 (2004) 53-59
21. Mattioli A.V., Zennaro M., Bonatti S., Bonetti L., and Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 97 (2004) 383-388
22. Ivanova O.V., Fomicheva O.A., Sergakova L.M., Chernova N.A., Rogoza A.N., and Karpov Y.A. Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension. J Int Med Res 33 suppl 1 (2005) 21A-29A
23. Petrovic I., Petrovic D., Vukovic N., Zivanovic B., Dragicevic J., Vasiljevic Z., and Babic R. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 33 suppl 1 (2005) 39A-49A
24. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R.A., Roniker B., Kleiman J., Krause S., Burns D., and Williams G.H. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation 108 (2003) 1831-1838
25. MacMahon S., Sharpe N., Gamble G., Clague A., Mhurchu C.N., Clark T., Hart H., Scott J., and White H. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 36 (2000) 438-443
26. Jennings G., and Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. J Hypertens Suppl 16 (1998) S29-S34
27. Cooper G.J.S., Young A.A., Gamble G.D., Occleshaw C.J., Dissanayake A.M., Cowan B.C., Brunton D.H., Baker J.R., Phillips A.R.J., Frampton C.M., Poppitt S.D., and Doughty R.N. Randomized controlled trial of trientine in type-2 diabetic patients with left ventricular hypertrophy and diastolic dysfunction. Diabetologia 52 (2009) 715-722
28. Cooper G.J.S., Phillips A.R.J., Choong S.Y., Leonard B.L., Crossman D.J., Brunton D.H., Saafi E.L., Dissanayake A.M., Cowan B.C., Young A.A., Occleshaw C.J., Chan Y.-K., Leahy F.E., Keogh G.F., Gamble G.D., Allen G.R., Pope A.J., Boyd P.D.W., Poppitt S.D., Borg T.K., Doughty R.N., and Baker J.R. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53 (2004) 2501-2508